===
EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report
26-Apr-2024 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News
- a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
April 26, 2024
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2024, which covers the results of
its business activities for the first three months of 2024.
Based on the consolidated accounts of BB Biotech AG, net profit for the period ended March 31, 2024 amounted to CHF 260
mn (loss of CHF 254 mn in the same period 2023). For an investment company, the results reflect the share price
development of the companies held in the portfolio.
The interim report as at March 31, 2024, is available under report.bbbiotech.ch/Q124 or www.bbbiotech.com.

For further information:
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch
www.bbbiotech.com
Company profile
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss
and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western
Europe. BB Biotech is one of the world's largest investors in this sector. The competent Board of Directors with its
long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced
investment management team of Bellevue Asset Management AG based on their extensive investment research.
End of Inside Information
26-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press
Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      BB BIOTECH AG 

Schwertstrasse 6
8200 Schaffhausen
Switzerland

Phone:        +41 52 624 08 45 
E-mail:       info@bbbiotech.com 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1889669 

End of Announcement EQS News Service
===
1889669 26-Apr-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1889669&application_name=news

END) Dow Jones Newswires

April 26, 2024 01:00 ET (05:00 GMT)